Neil Stahl Net Worth & Insider Trades
Neil Stahl - EVP Research and Development, Regeneron Pharmaceuticals, Inc
What is Neil Stahl's Net Worth?
The current estimated net worth of Regeneron Pharmaceuticals, Inc's EVP Research and Development, Neil Stahl, is estimated to be about $138.67M . Neil Stahl owns about 57,400 units of Regeneron Pharmaceuticals, Inc common stock. In the last 19 years at Regeneron Pharmaceuticals, Inc, Neil Stahl has sold an estimated value of $369.62M worth.
What is Neil Stahl's Past Insider Trading?
Neil Stahl's largest purchase order was 95,000 units , worth over $25.69M on August 8, 2022. Neil Stahl's largest sale order was 95,335 units , worth over $58.23M on August 8, 2022. In total, Neil Stahl has made about 63 transactions over 19 years of their time at Regeneron Pharmaceuticals, Inc. Neil Stahl usually trades in December, with the busiest year in 2014, 2020 and 2012.
Neil Stahl
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
Regeneron Pharmaceuticals, Inc Executive Compensation
Name |
Year
|
Salary
|
Stock Awards
|
Other Earnings Plans or Compensations
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
---|---|---|---|---|---|---|---|
Leonard S. Schleifer, M.D., Ph.D. | 2020 | $1,480,119 | $130,000,032 | $3,567,714 | $3,567,714 | $302,256 | $135,350,121 |
Leonard S. Schleifer, M.D., Ph.D. | 2019 | $1,377,100 | $4,983,226 | $3,057,162 | $3,057,162 | $338,043 | $21,455,117 |
Leonard S. Schleifer, M.D., Ph.D. | 2018 | $1,330,500 | - | $2,953,710 | $2,953,710 | $896,432 | $26,520,555 |
George D. Yancopoulos, M.D., Ph.D. | 2020 | $1,258,096 | $130,000,032 | $3,004,391 | $3,004,391 | $120,800 | $134,383,319 |
George D. Yancopoulos, M.D., Ph.D. | 2019 | $1,170,500 | $4,983,226 | $2,598,510 | $2,598,510 | $212,313 | $20,664,135 |
George D. Yancopoulos, M.D., Ph.D. | 2018 | $1,130,900 | - | $2,510,598 | $2,510,598 | $399,718 | $25,381,129 |
Robert E. Landry | 2020 | $825,577 | $949,560 | $938,872 | $938,872 | $24,195 | $6,197,703 |
Robert E. Landry | 2019 | $730,000 | $2,840,008 | $811,395 | $811,395 | $23,470 | $7,931,542 |
Robert E. Landry | 2018 | $680,000 | $4,767,500 | $581,400 | $581,400 | $19,535 | $9,356,619 |
Daniel P. Van Plew | 2020 | $825,577 | $3,409,560 | $938,872 | $938,872 | $20,945 | $8,654,453 |
Daniel P. Van Plew | 2019 | $683,100 | $2,840,008 | $759,266 | $759,266 | $20,470 | $7,829,513 |
Daniel P. Van Plew | 2018 | $660,000 | - | $677,160 | $677,160 | $19,915 | $9,007,222 |
Andrew J. Murphy, Ph.D. | 2020 | $726,923 | $5,025,288 | $887,250 | $887,250 | $24,195 | $10,998,914 |
Andrew J. Murphy, Ph.D. | 2019 | $600,000 | $4,702,308 | $666,900 | $666,900 | $23,470 | $9,519,347 |
No matching records found |
Source: https://www.sec.gov/Archives/edgar/data/872589/000093041321000869/c101011_def14a.htm
What are Regeneron Pharmaceuticals, Inc's Past Insider Trades?
Regeneron Pharmaceuticals, Inc's most recent insider trade came on March 27, 2023 by Bonnie L Bassler who sold 1,240 units worth $1.01M . In the last 20 years, insiders at Regeneron Pharmaceuticals, Inc have sold an estimated value of $17.55B and bought an estimated value of $3.54B worth of shares. Insider trading is most common in December, with the busiest year in 2014. The most active traders at the company are Joseph L Goldstein, Director, Michael S Brown, Director, and P. Roy Vagelos, Director .
REGENERON PHARMACEUTICALS, INC. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |